MediciNova, Inc. 10-Q Summary
Reporting period: Quarterly and six-month periods ended June 30, 2021; filed August 12, 2021. MediciNova is a development-stage biopharmaceutical company focused primarily on MN-166 (ibudilast) and MN-001 (tipelukast), with additional candidates MN-221 and MN-029. The company has no marketed products and has incurred significant losses since inception.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2021 | Comparable Period |
|---|---|---|---|
| Revenue | $0 | $4.0 million | $0 for Q2 2020; $0 for six months ended June 30, 2020 |
| Operating expenses | $4.3 million | $8.5 million | $4.5 million; $7.4 million |
| Operating loss | $4.3 million | $4.5 million | $4.5 million; $7.4 million |
| Net loss | $4.3 million | $4.5 million | $4.5 million; $7.2 million |
| Net loss per share | $0.09 | $0.09 | $0.10; $0.16 |
| Cash used in operating activities | Not separately provided | $2.7 million | $5.0 million |
Research, development and patent expense was $2.5 million in the quarter and $4.7 million year to date, driven primarily by MN-166 clinical development, including the ALS trial. General and administrative expense was $1.8 million in the quarter and $3.8 million year to date. Stock-based compensation expense was $0.8 million in the quarter and $1.9 million year to date.
Cash and cash equivalents were $77.8 million at June 30, 2021, compared with $60.0 million at December 31, 2020. Working capital was $76.4 million. Total liabilities were $4.4 million, including $2.5 million of current liabilities; the filing does not disclose outstanding debt. Management stated that available working capital was expected to fund operations at least through the end of 2022, although it cautioned that resources may not support all planned development programs.
Material Changes Versus Prior Comparable Period
- Six-month revenue increased by $4.0 million because two clinical development milestones under the Genzyme Agreement were achieved, generating milestone payments. This revenue was non-recurring in nature based on the information provided.
- Quarterly research and development expense increased by $0.3 million, primarily due to higher MN-166 ALS clinical trial costs.
- Six-month research and development expense increased by $1.2 million, primarily because of higher MN-166 clinical trial costs and stock-based compensation.
- Quarterly general and administrative expense decreased by $0.5 million, primarily due to lower performance-based stock compensation and lower consultant fees. Six-month expense decreased by $0.2 million, primarily due to lower legal expenses.
- Operating cash use declined by $2.2 million year over year, while financing cash flow increased to $20.5 million from $1.6 million.
- The company issued 3,656,307 shares in a January 2021 private placement for approximately $19.9 million of net proceeds. Shares outstanding increased to 48.9 million at June 30, 2021 from 45.0 million at December 31, 2020.
Guidance, Outlook, Risks and Unusual Items
- Management expects research and development spending to increase during 2021 as development programs progress and expects substantial net losses for the next several years.
- The company continues to enroll patients in clinical trials and reported that COVID-19-related reductions in patient visits had improved. Management did not expect a material negative impact on development plans, timelines or liquidity, but continues to monitor the pandemic.
- An Investigational New Drug application for MN-166 for prevention of COVID-19-related acute respiratory distress syndrome was accepted by the FDA, and the proposed clinical investigation was permitted to proceed.
- The company remains dependent on successful clinical development, regulatory approval, commercialization, partnerships and additional financing. Key risks include clinical-trial failure or delays, safety and efficacy concerns, regulatory uncertainty, reliance on third parties, intellectual-property disputes, competition, COVID-19 effects and inability to raise capital.
- The company has a $75.0 million at-the-market facility, but no shares were sold under it during the three or six months ended June 30, 2021.
- No material legal proceedings, material changes in risk factors, defaults or off-balance-sheet arrangements were reported.
- On July 20, 2021, the company entered into a 60-month headquarters lease beginning February 1, 2022, with monthly base rent starting at $14,464 and annual increases.
Investor Verification Items
- Verify the sustainability and collectability of the $4.0 million Genzyme milestone revenue and the timing of any additional milestone, royalty or sublicensing proceeds.
- Assess the clinical and regulatory status, enrollment, funding sources and expected costs for MN-166 and MN-001 programs.
- Reconcile projected cash runway through the end of 2022 with expected research and development spending, including potential financing needs.
- Review dilution from the private placement, stock options and any future use of the ATM facility.
- Monitor COVID-19 effects on trial enrollment, site activity, suppliers and development timelines.
- Evaluate the company’s accumulated deficit of $387.4 million and continued dependence on external financing or partnering.